Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04196413 · ClinicalTrials.gov registry record · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
A Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT04196413: Recruiting Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem, sponsored by Stanford University.
NCT04196413 is a Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem that is actively recruiting participants, run by Stanford University. The registered enrollment target is 97 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04196413, a Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG), the spinal cord, or other areas of the brain such as a thalamus
Primary Outcome
The percentage of apheresis samples (fresh or frozen) will be determined for each dose cohort.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG GD2 CAR T cells
Study Locations (1)
California
- Lucile Packard Children's Hospital (LPCH) - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2020-06-04 |
| Est. Completion | 2043-07-31 |
| Phase | Phase 1 |
What NCT04196413 shows while recruiting
NCT04196413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% higher).
The record links to 2 conditions, with Glioma of Spinal Cord appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04196413 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04196413 about?
NCT04196413 is a clinical study titled "GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)". The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG...
What is the current status of trial NCT04196413?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2020-06-04. Estimated completion is 2043-07-31.
What conditions does trial NCT04196413 study?
This clinical trial studies the following conditions: Glioma of Spinal Cord, Glioma of Brainstem.
What interventions are being tested in trial NCT04196413?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), GD2 CAR T cells (DRUG).
Who is sponsoring clinical trial NCT04196413?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04196413 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04196413's enrollment target sits among peer trials
97 598th of 2000 higher than 1,401 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
- NCT06076538 · 97 participants
PET/MR for Characterization of Renal Masses (RMs)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI